Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Overview of attention for article published in New England Journal of Medicine, March 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 10 news outlets
blogs: 2 blogs
twitter: 90 X users
patent: 12 patents
facebook: 7 Facebook pages

wikipedia: 1 Wikipedia page
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources

Readers on

mendeley: 488 Mendeley

So far, Altmetric has seen 14 news stories from 10 outlets.

Lessons learned from the PCSK9 inhibitor trials

Pediatric News , 15 Aug 2026

LOS ANGELES – Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce cardiovascular events in chronic and…

Lessons learned from the PCSK9 inhibitor trials

Pediatric News , 17 Dec 2024

Those are two key lessons from recent trials of PCSK9 inhibitors that Norman E.

Lessons learned from the PCSK9 inhibitor trials

Pediatric News , 25 Jan 2019

LOS ANGELES – Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce cardiovascular events in chronic and…

Mixed cardiovascular benefit with PCSK9 inhibitior bococizumab: The SPIRE trial | 2 Minute Medicine

2 Minute Medicine , 21 Apr 2017

1. When added to statin therapy, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor bococizumab significantly…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 10 additional news stories.